Supporting Australia’s brightest blood cancer minds
Making a difference to the lives of her patients is Dr Wei Jiang’s reason for getting up each morning.
Dr Jiang is just one of the talented researchers you will support when you fundraise in the lead up to Light the Night. Dr Jiang is a Leukaemia Foundation and Haematology Society of Australia and New Zealand PhD 2018 grant recipient – in her transition to full-time research after a decade working as a clinician.
Based at The Westmead Institute for Medical Research (Sydney), Dr Jiang is running two clinical trials to uncover how targeted therapies can alter the immune system to treat blood cancer.
“I chose to be a blood specialist and to study blood cancers because I discovered during my haematology training that making a difference in the lives of my patients was my reason for getting up each morning,” said Dr Jiang.
“Haematology is a rapidly changing field and I want to be a part of the science that changes people’s lives.”
Dr Jiang’s current grant funding enables her to run two therapeutic trials which will have significant clinical benefit for patients taking part.
“One trial involves the use of a new type of engineered immune cell, called CAR-T (chimeric antigen receptor T-cells) in the treatment of refractory B-cell leukemias and lymphomas,” said Dr Jiang.
“The other trial will look at use of pathogen-specific T-cells in the treatment of resistant viral infections in patients who have had stem cell transplants.
“Both trials use innovative, cutting-edge therapies that will contribute a genuine shift in treatment approaches in this field.”
When awarded the PhD grant, Dr Jiang said she was ‘humbled and even more excited to ‘crack on with it’!
“My ultimate goal is to be part of the development and discovery of a new blood cancer treatment that is effective, safe and universally affordable for everyone diagnosed, not only the lucky few.”
Thanks to your investment in new talent, like Dr Jiang, you’re ensuring blood cancer research continues to have significant and real-world outcomes for people living with blood cancer.
Back to news